Amag Pharmaceuticals (AMAG) Stock “Hold” Rating Kept at Piper Jaffray; The Target Price per Share is $18.0; Last Week Advanced Micro Devices, Inc. (AMD) Analysts

February 15, 2018 - By Migdalia James

Among 14 analysts covering AMAG Pharmaceuticals (NASDAQ:AMAG), 4 have Buy rating, 1 Sell and 9 Hold. Therefore 29% are positive. AMAG Pharmaceuticals has $89 highest and $15.0 lowest target. $27’s average target is 50.84% above currents $17.9 stock price. AMAG Pharmaceuticals had 38 analyst reports since August 18, 2015 according to SRatingsIntel. The company was maintained on Monday, July 24 by Cantor Fitzgerald. Cantor Fitzgerald maintained the stock with “Hold” rating in Thursday, February 1 report. Zacks downgraded the shares of AMAG in report on Wednesday, August 19 to “Strong-Buy” rating. The firm has “Hold” rating by Deutsche Bank given on Thursday, September 3. The stock of AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) earned “Hold” rating by Deutsche Bank on Thursday, November 19. The stock of AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) earned “Outperform” rating by Raymond James on Tuesday, September 1. The firm has “Outperform” rating given on Wednesday, May 4 by Leerink Swann. The firm has “Hold” rating given on Wednesday, November 4 by Deutsche Bank. The firm has “Market Perform” rating by Raymond James given on Wednesday, May 4. The stock of AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) has “Buy” rating given on Thursday, February 15 by Janney Capital.

Among 31 analysts covering Advanced Micro (NASDAQ:AMD), 12 have Buy rating, 6 Sell and 13 Hold. Therefore 39% are positive. Advanced Micro had 103 analyst reports since August 13, 2015 according to SRatingsIntel. Susquehanna initiated the stock with “Neutral” rating in Tuesday, September 20 report. The rating was maintained by Northland Capital on Tuesday, October 3 with “Buy”. The stock of Advanced Micro Devices, Inc. (NASDAQ:AMD) earned “Hold” rating by M Partners on Wednesday, January 10. The firm has “Buy” rating by Northland Capital given on Wednesday, June 21. The firm earned “Buy” rating on Wednesday, June 21 by Jefferies. Rosenblatt maintained the stock with “Buy” rating in Tuesday, January 30 report. Canaccord Genuity maintained the stock with “Buy” rating in Wednesday, July 12 report. As per Thursday, October 5, the company rating was maintained by KeyBanc Capital Markets. As per Friday, July 22, the company rating was maintained by Mizuho. The stock has “Buy” rating by Canaccord Genuity on Thursday, June 1. See Advanced Micro Devices, Inc. (NASDAQ:AMD) latest ratings:




12/02/2018 Broker: Robert W. Baird Rating: Buy New Target: $20.0 Maintain
01/02/2018 Broker: Argus Research Old Rating: Hold New Rating: Buy Upgrade
31/01/2018 Broker: Citigroup Rating: Sell New Target: $7.0 Maintain
31/01/2018 Broker: Credit Suisse Old Rating: Neutral New Rating: Neutral Old Target: $12 New Target: $13.5 Maintain
30/01/2018 Broker: Rosenblatt Rating: Buy New Target: $22.0 Maintain
29/01/2018 Broker: Susquehanna Rating: Hold New Target: $13.0 Maintain
29/01/2018 Broker: Longbow Rating: Hold
29/01/2018 Broker: M Partners Rating: Buy New Target: $14.5 Maintain
23/01/2018 Broker: Morgan Stanley Rating: Sell New Target: $8.0 Maintain
10/01/2018 Broker: M Partners Rating: Hold New Target: $13.0 Maintain

Investors sentiment increased to 1.51 in Q3 2017. Its up 0.23, from 1.28 in 2017Q2. It increased, as 39 investors sold Advanced Micro Devices, Inc. shares while 107 reduced holdings. 80 funds opened positions while 140 raised stakes. 559.57 million shares or 2.90% more from 543.78 million shares in 2017Q2 were reported. 415,616 were reported by Amp Capital Invsts. Royal National Bank & Trust Of Canada has invested 0% in Advanced Micro Devices, Inc. (NASDAQ:AMD). World Invsts holds 0.01% in Advanced Micro Devices, Inc. (NASDAQ:AMD) or 2.00 million shares. Supplemental Annuity Collective Of Nj invested in 0.34% or 60,000 shares. Twin Tree Limited Partnership has 900,442 shares for 0.09% of their portfolio. Lord Abbett Ltd holds 0.01% of its portfolio in Advanced Micro Devices, Inc. (NASDAQ:AMD) for 190,604 shares. Cwm Ltd Liability owns 8,199 shares. Cornerstone Capital Management Holding Limited Com reported 138,151 shares. Victory Cap Mgmt Incorporated reported 13,281 shares. Advantus Mgmt Inc stated it has 81,746 shares. Avalon Ltd Liability invested in 0.28% or 697,912 shares. Marathon Trading Inv Management Ltd has 19,000 shares for 0.03% of their portfolio. Robeco Institutional Asset Management Bv invested 0% of its portfolio in Advanced Micro Devices, Inc. (NASDAQ:AMD). Exane Derivatives reported 6,206 shares. Valley National Advisers Inc stated it has 14 shares or 0% of all its holdings.

The stock increased 0.16% or $0.02 during the last trading session, reaching $12.22. About 33.04M shares traded. Advanced Micro Devices, Inc. (NASDAQ:AMD) has risen 202.65% since February 15, 2017 and is uptrending. It has outperformed by 185.95% the S&P500.

Since August 14, 2017, it had 0 buys, and 18 sales for $19.93 million activity. $906,556 worth of Advanced Micro Devices, Inc. (NASDAQ:AMD) was sold by WOLIN HARRY A. 75,000 shares were sold by ANDERSON JAMES ROBERT, worth $752,250 on Thursday, December 14. $4.05 million worth of Advanced Micro Devices, Inc. (NASDAQ:AMD) shares were sold by Su Lisa T. Norrod Forrest Eugene had sold 62,500 shares worth $766,625. On Monday, January 15 the insider KUMAR DEVINDER sold $1.41 million. The insider SMITH DARLA M sold 22,175 shares worth $270,535. Another trade for 173,630 shares valued at $2.10 million was made by Papermaster Mark D on Monday, January 15.

Advanced Micro Devices, Inc. operates as a semiconductor firm worldwide. The company has market cap of $11.79 billion. The Company’s primarily offers x86 microprocessors as an accelerated processing unit , chipsets, discrete graphics processing units (GPUs), and professional graphics; and server and embedded processors, and semi-custom System-on-Chip (SoC) products and technology for game consoles. It has a 305.5 P/E ratio. The firm provides x86 microprocessors for desktop PCs under the AMD A-Series, AMD E-Series, AMD FX CPU, AMD Athlon CPU and APU, AMD Sempron APU and CPU, and AMD Pro A-Series APU brands; and microprocessors for notebook and 2-in-1s under the AMD A-Series, AMD E-Series, AMD C-Series, AMD Z-Series, AMD FX APU, AMD Phenom, AMD Athlon CPU and APU, AMD Turion, and AMD Sempron APU and CPU brand names.

AMAG Pharmaceuticals, Inc., a biopharmaceutical company, makes, develops, and commercializes therapeutics for womenÂ’s health, anemia management, and cancer supportive care in the United States. The company has market cap of $633.20 million. It markets Makena, a hydroxyprogesterone caproate injection to reduce the risk of preterm birth in women pregnant with a single baby who have a history of singleton spontaneous preterm birth; Feraheme , an intravenous iron replacement therapeutic agent for the treatment of iron deficiency anemia in adult patients with chronic kidney disease; and MuGard Mucoadhesive Oral Wound Rinse for the management of oral mucocitis/stomatiits and various types of oral wounds. It currently has negative earnings. The firm also offers Cord Blood Registry services that are related to the collection, processing, and storage of umbilical cord blood and cord tissue units for pregnant women and their families.

Since August 29, 2017, it had 0 insider buys, and 1 sale for $20,938 activity. Shares for $20,938 were sold by Vittiglio Joseph on Tuesday, August 29.

The stock increased 28.78% or $4 during the last trading session, reaching $17.9. About 8.56 million shares traded or 921.06% up from the average. AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) has risen 3.00% since February 15, 2017 and is uptrending. It has underperformed by 13.70% the S&P500.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.




Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: